1. Home
  2. UTL vs DSGN Comparison

UTL vs DSGN Comparison

Compare UTL & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo UNITIL Corporation

UTL

UNITIL Corporation

SELL

Current Price

$54.07

Market Cap

944.1M

Sector

Utilities

ML Signal

SELL

Logo Design Therapeutics Inc.

DSGN

Design Therapeutics Inc.

HOLD

Current Price

$10.38

Market Cap

853.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
UTL
DSGN
Founded
1984
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Power Generation
Biotechnology: Pharmaceutical Preparations
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
944.1M
853.8M
IPO Year
1995
2021

Fundamental Metrics

Financial Performance
Metric
UTL
DSGN
Price
$54.07
$10.38
Analyst Decision
Hold
Strong Buy
Analyst Count
3
8
Target Price
★ $54.00
$21.71
AVG Volume (30 Days)
126.6K
★ 601.9K
Earning Date
11-02-2026
11-04-2026
Dividend Yield
★ 3.56%
N/A
EPS Growth
★ 1.37
N/A
EPS
★ 2.11
N/A
Revenue
★ $536,000,000.00
N/A
Revenue This Year
$16.49
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$25.27
★ N/A
Revenue Growth
★ 8.33
N/A
52 Week Low
$46.91
$5.28
52 Week High
$57.26
$17.25

Technical Indicators

Market Signals
Indicator
UTL
DSGN
Relative Strength Index (RSI) 65.48 33.05
Support Level $52.10 $9.78
Resistance Level $54.96 $11.18
Average True Range (ATR) 1.02 0.65
MACD 0.38 -0.14
Stochastic Oscillator 93.57 27.06

Price Performance

Historical Comparison
UTL
DSGN

About UTL UNITIL Corporation

Unitil Corp through its subsidiaries engages in the distribution of electricity and natural gas in its service territories in the states of New Hampshire, Massachusetts and Maine. Its natural gas operations include gas distribution utility operations and interstate gas transmission pipeline operations. It also engages in interstate natural gas transmission pipeline company, operating approximately 85 miles of underground gas transmission pipeline located in Maine and New Hampshire. The company's segments include Electric and Gas.

About DSGN Design Therapeutics Inc.

Design Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the research and development of GeneTAC molecules, which are a novel class of small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its pipeline includes Friedreich Ataxia, FECD, DM1, and Huntington's Disease. The company operates in one operating and reportable segment focused on utilizing the company's proprietary GeneTAC platform to design and develop therapeutic candidates for inherited diseases driven by nucleotide repeat expansion.

Share on Social Networks: